Bial reports additional data from Ongentys in Parkinson’s patients

Bial has reported new efficacy and tolerability data from Ongentys (opicapone), a catechol-O-methyltransferase (COMT) inhibitor, in Phase III studies involving patients with Parkinson's disease (PD) and Movement Disorders (MDS).